Clinical Analysis Of HAA Induction Regimen For Newly Diagnosed And Refractory/Relapsed Acute Myeloid Leukemia

Objective:To analyze the efficacy and safety of HAA induction regimen consisted of Homoharringtonine (HHT), Cytarabine (Ara-C) and Aclacinomycin (ACM) in naive and refractory/relapsed acute myeloid leukemia(AML).Methods:The data of66cases with AML hospitalized in our center and treated with HAA induction regimen was analyzed retrospectively. All patients underwent HAA induction regimen, that is, HHT1.5mg/m2qd (5-7days), Ara-C100-150mg/m2qd (5-7days), ACM12-15mg/m2qd (5-7days).Results:45out of66cases suffered from naive AML, and21refractory/relapsed AML. The efficacy of HAA induction regimen in naive AML was evaluated in41cases with36in complete remission(CR) and1in partial remission(PR). The CR rate of HAA induction regimen was87.8%in naive AML group and42.9%in refractory/relapsed group respectively. There were no differences in CR rate by patient’s gender, age, FAB subtype and white blood cell(WBC) counts at onset(P>0.05). Fourteen patients with naive AML in CR were followed-up in a median time of9months (2-17months), and five out of them relapsed(35.7%) in a range of2-8months post CR. The median myelosuppression duration in all patients was14days (3-23days). The major side effects of HAA regimen included myelosuppression(100%), chemotherapy related infection(53%), nausea and vomiting (28.8%) and abdominal pain and diarrhea(9%). Other non-hematological toxicities were rare or mild.Conclusion HAA induction regimen may be a fine choice for the induction chemotherapy in patients with naive and relapsed/refractory AML.